William L. Redmond, Ph.D.

redmondheadshot

Contact William L. Redmond, Ph.D.
Associate Member, Laboratory of Cancer Immunotherapy
Director, Immune Monitoring Laboratory
Earle A. Chiles Research Institute
Providence Cancer Institute

Adjunct Assistant Professor, Department of Molecular Microbiology and Immunology
Oregon Health & Science University

The goal of our research is to understand how combination immunotherapy synergizes to augment CD8 T cell-mediated anti-tumor immunity. Our previous studies helped elucidate the mechanisms by which OX40 agonist immunotherapy plus checkpoint blockade synergized with a novel cancer vaccine to boost the function of killer CD8 T cells and cause tumor regression. Currently, we are investigating how combination immunotherapy restores the function of killer CD8 T cells that have been paralyzed, or rendered anergic, by tumors. Additional studies seeks to understand the mechanisms by which immunotherapy enhances the efficacy of conventional treatments, such as radiation therapy, with the goal of providing a path for rapid translation to the clinic. Learn more about Dr. Redmond’s research.

Training

Education

  • Post-doctoral Fellow, Earle A. Chiles Research Institute, Providence Portland Medical Center, 2004-2009
  • Ph.D., The Scripps Research Institute, La Jolla, Calif., 2004
  • BS, University of California at Davis, Davis, Calif., 1997

Professional Experience

  • Director, Immune Monitoring Laboratory, Earle A. Chiles Research Institute, Providence Cancer Center, 2016-present
  • Associate Member, Laboratory of Cancer Immunotherapy, Earle A. Chiles Research Institute, Providence Cancer Center, 2009-present
  • Adjunct Assistant Professor, Oregon Health & Science University, Department of Molecular Microbiology and Immunology, 2012-Present
  • Post-doctoral Fellow, Earle A. Chiles Research Institute, Providence Cancer Center, 2004-2009

Memberships & Awards

Memberships

  • Society for Immunotherapy of Cancer (SITC)
  • American Association of Immunologists (AAI)
  • American Association for Cancer Research (AACR) 

Honors & Awards

  • Susan G. Komen – Career Catalyst Research Grant (2015-2018)
  • V Foundation - V Scholar Award (2011-2013)
  • American Association of Immunologists, Junior Faculty Travel Grant, AAI Annual Meeting, San Francisco, Calif. (2011)
  • American Association of Immunologists, Cynthia Chambers Memorial - eBioscience Junior Faculty Award, AAI Annual Meeting, San Francisco, Calif. (2011)
  • NIH/NCI - Pathway to Independence Award (K99) (2010-2014)
  • Prostate Cancer Foundation - Young Investigator Award (2008-2011)
  • American Cancer Society - Sam E. and Kathleen L. Henry Post-doctoral Fellowship (2006-2009)
  • American Association of Immunologists - Trainee Abstract Award, AAI Annual Meeting, Seattle, Wash. (2009)
  • American Association of Immunologists - Trainee Abstract Award, AAI Annual Meeting, San Diego, Calif. (2008)
  • Achievement Rewards for College Scientists (ARCS) Foundation - Scholar, Pre-doctoral Fellowship (2001-2004)

Publications

McNamara MJ, Hilgart-Martiszus I, Echenique DMB, Kasiewicz MJ, Redmond WL. Interferon-γ production by peripheral lymphocytes predicts survival of tumor-bearing mice receiving dual PD-1/CTLA-4 blockade. Cancer Immunology Research 4(8), 650-7, (2016), doi: 10.1158/2326-6066.CIR-16-0022. 

Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus I, Mohammad F, Redmond WL. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice. Proceedings of the National Academy of Sciences, 113(3), (2016). doi:10.1073/pnas.1510518113. PMC4725491.

Linch SN, Redmond WL. Commentary: How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy. Journal for ImmunoTherapy of Cancer, 4(31), (2016), doi: 10.1186/s40425-016-0135-z.

Redmond WL, Linch SN. Commentary: Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells. Human Vaccines and Immunotherapeutics, Jul 26:1-4, (2016). doi:10.1080/21645515.2016.1193277.

Linch SN, McNamara MJ, Redmond WL. OX40 agonists and combination immunotherapy: putting the pedal to the metal. Frontiers in Oncology, 5(34), (2015). doi:10.3389/fonc.2015.00034. PMC4329814.

Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity. Cancer Immunology Research, 2(2), 142-153 (2014). PMC4007342.

View Dr. Redmond’s full list of peer-reviewed publications.